Old Web
English
Sign In
Acemap
>
authorDetail
>
Faye Coe
Faye Coe
Breast cancer
Medicine
Carboplatin
Chemotherapy
Oncology
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer.
2021
Breast Cancer Research and Treatment
Faye Coe
Vivek Misra
Yamini Mccabe
Helen Adderley
Laura Woodhouse
Zaheen Ayub
Xin Wang
Sacha J Howell
Maria Ekholm
Show All
Source
Cite
Save
Citations (0)
Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP).
2020
Breast Cancer Research and Treatment
Sacha J Howell
Faye Coe
Xin Wang
Laura Horsley
Maria Ekholm
Show All
Source
Cite
Save
Citations (0)
(Neo)adjuvant carboplatin-based chemotherapy in the treatment of triple negative early breast cancer – experience at a single UK institution.
2018
European Journal of Cancer
Anne C Armstrong
Faye Coe
Suzanne Frank
Sacha J Howell
P. Wright
Yamini Mccabe
Daryl Morris
Andrew M Wardley
Show All
Source
Cite
Save
Citations (0)
1